FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394428> ?p ?o ?g. }

• W4308394428 abstract "<h3>Background</h3> METTL3 is an RNA methyltransferase responsible for the deposition of N-6-methyladenosine (m⁶A) modification on mRNA and long non-coding RNA (lncRNA) transcripts, to regulate their stability, splicing, transport and translation. Small molecule inhibitors of METTL3 catalytic activity have previously demonstrated direct anti-tumour efficacy in models of acute myeloid leukemia (AML). Here we present pre-clinical data showing that STC-15, an orally bioavailable small molecule inhibitor of METTL3, restrains cancer growth and induces anti-cancer immunity <h3>Methods</h3> To characterise transcriptomic changes following METTL3 inhibition, RNA sequencing studies were performed on several cancer cell lines treated with STC-15. Induction of specific genes was validated by qPCR and Western Blots. The functional consequence of the upregulation of innate immune pathways was investigated in vitro using a co-culture system of SKOV3 ovarian cancer cells and human peripheral blood mononuclear cells (PBMC) or purified primary CD8+ T-cells, and animal studies using subcutaneous A20 and MC38 mouse syngeneic tumour models <h3>Results</h3> Inhibition of METTL3 by STC-15 in cancer cell lines leads to prominent upregulation of genes associated with innate immunity, including type-I and type-III IFNs, as well as many interferon stimulated genes. Cells treated with STC-15 accumulated double-stranded RNA suggesting that activation of IFN signalling is triggered by innate pattern recognition sensors. In an in vitro co-culture system, STC-15 demonstrated strong and dose-dependent enhancement of PBMC-mediated killing of cancer cells. Similar results were obtained when replacing PBMC with purified CD8+ T-cells. In MC38 colorectal and A20 lymphoma syngeneic models, oral treatment of immune-competent tumour bearing mice with STC-15 significantly inhibited tumour growth. In vivo depletion of CD8+ T-cells abrogated the response to STC-15. Combination of STC-15 with anti-PD1 antibody resulted in tumour regression in both models, with mice remaining tumour-free long after treatment ceased. When regressed mice from the A20 model were re-challenged with a new batch of A20 cells, no new tumour growth was observed, further demonstrating the induction of durable anti-tumour immunity <h3>Conclusions</h3> In pre-clinical cancer models, STC-15 treatment results in activation of innate immune pathways, inhibits tumour growth via activation of CD8+ T-cell mediated tumour cell killing, and enhances the anti-tumour properties of anti-PD1 therapy to generate a durable anti-tumour immune response. These data provide the rationale for the development of STC-15 both as monotherapy and in combination with checkpoint inhibition for the treatment of solid tumour malignancies. A Phase I, First-in-Human clinical trial is planned to begin in 2022 <h3>Ethics Approval</h3> Animal welfare for this study complies with the UK Animals Scientific Procedures Act 1986 (ASPA) in line with Directive 2010/63/EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes." @default.
• W4308394428 created "2022-11-11" @default.
• W4308394428 creator A5001638689 @default.
• W4308394428 creator A5001662498 @default.
• W4308394428 creator A5012391688 @default.
• W4308394428 creator A5021778124 @default.
• W4308394428 creator A5049090059 @default.
• W4308394428 creator A5053331499 @default.
• W4308394428 creator A5053939329 @default.
• W4308394428 creator A5062438131 @default.
• W4308394428 creator A5068091975 @default.
• W4308394428 creator A5068214363 @default.
• W4308394428 creator A5086547100 @default.
• W4308394428 date "2022-11-01" @default.
• W4308394428 modified "2023-09-25" @default.
• W4308394428 title "1373 STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergises with immune checkpoint blockade" @default.
• W4308394428 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1373" @default.
• W4308394428 hasPublicationYear "2022" @default.
• W4308394428 type Work @default.
• W4308394428 citedByCount "0" @default.
• W4308394428 crossrefType "proceedings-article" @default.
• W4308394428 hasAuthorship W4308394428A5001638689 @default.
• W4308394428 hasAuthorship W4308394428A5001662498 @default.
• W4308394428 hasAuthorship W4308394428A5012391688 @default.
• W4308394428 hasAuthorship W4308394428A5021778124 @default.
• W4308394428 hasAuthorship W4308394428A5049090059 @default.
• W4308394428 hasAuthorship W4308394428A5053331499 @default.
• W4308394428 hasAuthorship W4308394428A5053939329 @default.
• W4308394428 hasAuthorship W4308394428A5062438131 @default.
• W4308394428 hasAuthorship W4308394428A5068091975 @default.
• W4308394428 hasAuthorship W4308394428A5068214363 @default.
• W4308394428 hasAuthorship W4308394428A5086547100 @default.
• W4308394428 hasBestOaLocation W43083944281 @default.
• W4308394428 hasConcept C104317684 @default.
• W4308394428 hasConcept C121608353 @default.
• W4308394428 hasConcept C127561419 @default.
• W4308394428 hasConcept C136449434 @default.
• W4308394428 hasConcept C150194340 @default.
• W4308394428 hasConcept C153911025 @default.
• W4308394428 hasConcept C162317418 @default.
• W4308394428 hasConcept C203014093 @default.
• W4308394428 hasConcept C2777701055 @default.
• W4308394428 hasConcept C2780851360 @default.
• W4308394428 hasConcept C502942594 @default.
• W4308394428 hasConcept C54355233 @default.
• W4308394428 hasConcept C55493867 @default.
• W4308394428 hasConcept C86803240 @default.
• W4308394428 hasConcept C8891405 @default.
• W4308394428 hasConcept C96232424 @default.
• W4308394428 hasConceptScore W4308394428C104317684 @default.
• W4308394428 hasConceptScore W4308394428C121608353 @default.
• W4308394428 hasConceptScore W4308394428C127561419 @default.
• W4308394428 hasConceptScore W4308394428C136449434 @default.
• W4308394428 hasConceptScore W4308394428C150194340 @default.
• W4308394428 hasConceptScore W4308394428C153911025 @default.
• W4308394428 hasConceptScore W4308394428C162317418 @default.
• W4308394428 hasConceptScore W4308394428C203014093 @default.
• W4308394428 hasConceptScore W4308394428C2777701055 @default.
• W4308394428 hasConceptScore W4308394428C2780851360 @default.
• W4308394428 hasConceptScore W4308394428C502942594 @default.
• W4308394428 hasConceptScore W4308394428C54355233 @default.
• W4308394428 hasConceptScore W4308394428C55493867 @default.
• W4308394428 hasConceptScore W4308394428C86803240 @default.
• W4308394428 hasConceptScore W4308394428C8891405 @default.
• W4308394428 hasConceptScore W4308394428C96232424 @default.
• W4308394428 hasLocation W43083944281 @default.
• W4308394428 hasOpenAccess W4308394428 @default.
• W4308394428 hasPrimaryLocation W43083944281 @default.
• W4308394428 hasRelatedWork W1861033863 @default.
• W4308394428 hasRelatedWork W2344637265 @default.
• W4308394428 hasRelatedWork W2465295184 @default.
• W4308394428 hasRelatedWork W2973429485 @default.
• W4308394428 hasRelatedWork W2978620875 @default.
• W4308394428 hasRelatedWork W4210499236 @default.
• W4308394428 hasRelatedWork W4241300757 @default.
• W4308394428 hasRelatedWork W4283731173 @default.
• W4308394428 hasRelatedWork W4291367166 @default.
• W4308394428 hasRelatedWork W4308359949 @default.
• W4308394428 isParatext "false" @default.
• W4308394428 isRetracted "false" @default.
• W4308394428 workType "article" @default.